Drug Profile
Tebotelimab - MacroGenics
Alternative Names: Anti-LAG-3 bispecific DART protein; MGD-013; PD-1 x LAG-3 bispecific DART molecule; PD-1 X LAG-3 DARTLatest Information Update: 23 Mar 2023
Price :
$50
*
At a glance
- Originator MacroGenics
- Developer MacroGenics; ZAI Lab
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Gastric cancer; Oesophageal cancer
- Phase II Head and neck cancer
- Phase I Haematological malignancies; Solid tumours
- Discontinued Biliary cancer; Cholangiocarcinoma; Endometrial cancer; Liver cancer; Malignant melanoma; Triple negative breast cancer
Most Recent Events
- 23 Mar 2023 Tebotelimab is still in phase I trials for Haematological malignancies and Solid tumours in Australia, Bulgaria, Poland, Spain, Thailand, USA and Ukraine
- 08 Feb 2023 MacroGenics completes a phase I trial for Solid tumors and Haematological malignancies (Combination therapy, Late stage disease, Metastatic disease, Inoperable/Unresectable) in USA, Australia, Bulgaria, Hong Kong, Poland, Spain, Thailand, Ukraine (IV) (NCT03219268)
- 08 Feb 2023 MacroGenics completes a phase I trial for Solid tumors and Haematological malignancies (Monotherapy, Late stage disease, Metastatic disease, Inoperable/Unresectable) in USA, Australia, Bulgaria, Hong Kong, Poland, Spain, Thailand, Ukraine (IV) (NCT03219268)